Skip to content
Triangle logo TriangleGet started
← Multiple Myeloma

NCT00040937 · STUDY IN CONTEXT

S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Overall Survival

Source null

→

secondary · POSTED

To assess Grade 3-5 AE related to thalidomide/dexamethasone when administered as a pre-transplant induction regimen.

All participants receiving at least one dose of induction therapy

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-multiple-myeloma
nct id
NCT00040937
trial label
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
applicability
narrower
applicability note
Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
2
harms Count
3
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00040937
    outcome key
    om-0001
    source section id
    NCT00040937-om-0001
    source outcome index
    1
    endpoint
    Overall Survival
    endpoint definition
    Overall Survival
    time origin
    4-7 years
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00040937
    outcome key
    om-0000
    source section id
    NCT00040937-om-0000
    source outcome index
    0
    endpoint
    Assess Toxicity of Thalidomide/Dexamethasone as a Pre-transplant Induction Regimen.
    endpoint definition
    To assess Grade 3-5 AE related to thalidomide/dexamethasone when administered as a pre-transplant induction regimen.
    time origin
    Induction
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    All participants receiving at least one dose of induction therapy
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00040937
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Induction/PBSC Mobilization
    regimen
    Induction/PBSC Mobilization
    analyzed count
    140
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00040937-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00040937
    outcome key
    om-0001
    arm key
    OG000
    arm label
    Treatment Arm
    regimen
    thalidomide/dexamethasone followed by tandem melphalan peripheral blood stem cell transplantation (with cyclophosphamide and filgrastim or sargramostim support) and prednisone/thalidomide maintenance
    analyzed count
    142
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00040937-om-0001#groups/OG000
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00040937
    harm key
    EG000
    source section id
    NCT00040937-ae
    event group key
    EG000
    event group label
    Induction/PBSC Mobilization
    serious affected
    7
    serious at risk
    140
    other affected
    140
    other at risk
    140
    frequency threshold
    5
    collection period
    Report through 4/10/2007 to match data reported in MS.
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00040937
    harm key
    EG001
    source section id
    NCT00040937-ae
    event group key
    EG001
    event group label
    Autologous PBSCT
    serious affected
    0
    serious at risk
    105
    other affected
    105
    other at risk
    105
    frequency threshold
    5
    collection period
    Report through 4/10/2007 to match data reported in MS.
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-multiple-myeloma
    nct id
    NCT00040937
    harm key
    EG002
    source section id
    NCT00040937-ae
    event group key
    EG002
    event group label
    Prednisone + Thalidomide
    serious affected
    1
    serious at risk
    76
    other affected
    74
    other at risk
    76
    frequency threshold
    5
    collection period
    Report through 4/10/2007 to match data reported in MS.
    event definition
    Source null
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice